Search

Displaying results 1351 - 1360 of 3889 in total
  1. Drug

    Teriparatide

    go.drugbank.com/drugs/DB06285
    ApprovedInvestigational

    Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Eu...

    Categories: Sex Hormones and Insulins
  2. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal

  3. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675]

  4. Drug

    Tibolone

    go.drugbank.com/drugs/DB09070
    ApprovedInvestigational

    Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha . Tibolone (Livial, Org OD 14), produced by Org...

    Categories: Genito Urinary System and Sex Hormones, Sex Hormones and Modulators of the Genital System
  5. Drug

    Coenzyme M

    go.drugbank.com/drugs/DB09110
    ApprovedInvestigational

    Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

  6. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.

    Categories: HCV Replication Complex Inhibitors
  7. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    [A249030] Each dose of axicabtagene ciloleucel represent the patient's genetically modified T-cells. … [L40054] Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018.[L42090]

    Categories: Complex Mixtures
  8. Drug

    Lefamulin

    go.drugbank.com/drugs/DB12825
    Approved

    [L8093] This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. … [A183161] The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.[A183167]

  9. Drug

    Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB18750
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

    Mixtures: Fluzone High Dose Northern Hemisphere, FLUZONE High-Dose Quadrivalent Southern Hemisphere
  10. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Aust...